Skip to main content
SpringerLink
Log in

Von der Chemotherapie zur „targeted therapy“

Behandlung follikulärer Lymphome

  • zertifizierte fortbildung
  • Published:
Info Onkologie Aims and scope

Zusammenfassung

Das follikuläre Lymphom ist das häufigste indolente Lymphom. Es zeichnet sich durch einen langen, chronischen Verlauf aus. Eine Heilung ist bislang nicht möglich. Die Indikation zur Therapie muss individuell gestellt werden. Behandelt wird in fortgeschrittenen Stadien, in der Regel nur bei krankheitsassoziierten Symptomen, wie einer B-Symptomatik, einer hämatopoetischen Insuffizienz, bei Vorhandensein eines großen verdrängenden Lymphombulks oder bei einer raschen Krankheitsprogredienz.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2
3

Literatur

  1. Aisenberg AC. Malignant Lymphoma: Biology, natural history, and treatment. Erste Auflage. Philadelphia, London: Lea and Febiger; 1991.

    Google Scholar 

  2. McLaughlin P et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825–33.

    CAS  PubMed  Google Scholar 

  3. Swerdlow S et al. WHO classification of tumours of haematopoetic and lymphoid tissues. Vierte Auflage. Genf: WHO; 2008.

    Google Scholar 

  4. Montoto S, Fitzgibbon J. Transformation of indolent B-cell lymphomas. J Clin Oncol. 2011;29(14):1827–34.

    Article  PubMed  Google Scholar 

  5. Solal-Celigny P et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–65.

    Article  CAS  PubMed  Google Scholar 

  6. Federico M et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555–62.

    Article  PubMed  Google Scholar 

  7. Lowry L et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1):86–92.

    Article  PubMed  Google Scholar 

  8. Pugh TJ et al. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2010;116(16):3843–51.

    Article  PubMed  Google Scholar 

  9. Herfarth K, Schnaidt S. Early stage nodal follicular lymphoma using IF radiotherapy and Rituximab: Results of the MIR trial of the GLSG and ARO. Radiat Oncol (33rd ESTRO Meeting). 2014;111(Supl 1):Abstr 1098-PD.

    Google Scholar 

  10. Colombat P et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97(1):101–6.

    Article  CAS  PubMed  Google Scholar 

  11. Friedberg JW et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27(8):1202–8.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Ardeshna KM et al. An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis. Blood (ASH Annual Meeting Abstracts). 2010;116(21):Abstr 6.

    Google Scholar 

  13. Ardeshna KM et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15(4):424–35.

    Article  CAS  PubMed  Google Scholar 

  14. Schulz H et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99(9):706–14.

    Article  CAS  PubMed  Google Scholar 

  15. Rummel MJ et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–10.

    Article  CAS  PubMed  Google Scholar 

  16. Federico M et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31(12):1506–13.

    Article  CAS  PubMed  Google Scholar 

  17. Dreyling M et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii76–82.

    Article  Google Scholar 

  18. Vidal L et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2011;103(23):1799–806.

    Article  CAS  PubMed  Google Scholar 

  19. Salles G et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51.

    Article  CAS  PubMed  Google Scholar 

  20. Forstpointner R et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108(13):4003–8.

    Article  CAS  PubMed  Google Scholar 

  21. van Oers MH et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Taverna CJ et al. Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03. Blood (ASH Annual Meeting Abstracts). 2013;122(21):Abstr 508.

    Google Scholar 

  23. Kahl BS et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol. 2014;32(28):3096–102.

    Article  CAS  PubMed  Google Scholar 

  24. Morschhauser F et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-Line Indolent trial. J Clin Oncol. 2013;31(16):1977–83.

    Article  CAS  PubMed  Google Scholar 

  25. Lopez-Guillermo A et al. A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90y Ibritumomab Tiuxetan (Zevalin®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization. Blood (ASH Annual Meeting Abstracts). 2013;122(21):Abstr 369.

    Google Scholar 

  26. Montoto S et al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica. 2013;98(7):1014–21.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Hiddemann W et al. Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lymphoma After Initial Immuno-Chemotherapy (R-CHOP) Or Chemotherapy Alone: Analysis Of 940 Patients Treated In Prospective Randomized Trials Of The German Low Grade Lymphoma Study Group (GLSG). Blood (ASH Annual Meeting Abstracts). 2013;122(21):Abstr 419.

    Google Scholar 

  28. Sebban C et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol. 2008;26(21):3614–20.

    Article  CAS  PubMed  Google Scholar 

  29. Czuczman MS et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012;119(16):3698–704.

    Article  CAS  PubMed  Google Scholar 

  30. Salles G et al. Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients — Updated Results with Encouraging Progression Free Survival (PFS) Data From a Phase II Study In Patients with Relapsed/Refractory Indolent NHL (iNHL). Blood (ASH Annual Meeting Abstracts). 2010;116(21):Abstr 2868.

    Google Scholar 

  31. Radford J et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood. 2013;122(7):1137–43.

    Article  CAS  PubMed  Google Scholar 

  32. Viardot A et al. Eine offene Phase-2-Studie mit dem bi-spezifischen „T-cell engager’ (BiTE (R) ) Antikörper Blinatumomab bei Patienten mit rezidiviertem/therapierefraktärem diffusem großzelligen B-Zell-Lymphom. Oncol Res Treat (DGHO-Jahrestagung). 2014;37(suppl 5):Abstr 225.

    Google Scholar 

  33. Bargou R et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321(5891):974–7.

    Article  CAS  PubMed  Google Scholar 

  34. Advani A et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085–93.

    Article  CAS  PubMed  Google Scholar 

  35. Morschhauser F et al. Preliminary Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin (PoV) or Pinatuzumab Vedotin (PiV) Plus Rituximab (RTX) in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. J Clin Oncol (ASCO Annual Meeting Abstracts). 2014;32(suppl);Abstr 8519.

    Google Scholar 

  36. Coiffier B et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol. 2011;12(8):773–84.

    Article  CAS  PubMed  Google Scholar 

  37. Witzig TE et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma. J Clin Oncol. 2009;27(32):5404–9.

    Article  CAS  PubMed  Google Scholar 

  38. Fowler NH et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15(12):1311–8.

    Article  CAS  PubMed  Google Scholar 

  39. Pro B et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol. 2008;143(3):355–60.

    Article  CAS  PubMed  Google Scholar 

  40. Gopal AK et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–18.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Flinn IW et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014;123(22):3406–13.

    Article  CAS  PubMed  Google Scholar 

  42. Ponader S et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182–9.

    Article  CAS  PubMed  Google Scholar 

  43. Advani RH et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88–94.

    Article  CAS  PubMed  Google Scholar 

  44. Smith SM et al. Temsirolimus has activity in non-mantle cell non-Hodgkin’s lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010;28(31):4740–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Hess G. Temsirolimus added to bendamustin and Rituximab (BERT): phase I results of a phase I/II-trial in patients with relapsed follicular lymphoma (FL) and mantle cell lymphoma (MCL). Hematol Oncol (12th International Conference on Malignant Lymphoma). 2013;31(Suppl 1):Abstr 149.

    Google Scholar 

  46. Feuerlein K et al. First-line treatment of follicular lymphoma: a patient-oriented algorithm. Leuk Lymphoma. 2009;50(3):325–34.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik III, Campus Großhadern der LMU München, Marchioninistraße 15, 81377, München, Deutschland

    Roswitha Forstpointner & Martin Dreyling

Authors
  1. Roswitha Forstpointner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Dreyling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roswitha Forstpointner.

Additional information

Interessenkonflikt

Dr. med. Roswitha Forstpointner und Prof. Dr. med. Martin Dreyling erklären, dass sie sich bei der Erstellung des Beitrags von keinerlei wirtschaftlichen Interessen leiten ließen. Als Gegenstand möglicher Interessenkonflikte gibt Prof. Dreyling an: Rednerhonorare: Celgene, Gilead, Janssen, Mundipharma, Pfizer, Roche; scientific Advisory Boards: Bayer, Celgene, Janssen. Support für Investigator-initiated-Trials: Celgene, Janssen, Mundipharma, Pfizer, Roche. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Forstpointner, R., Dreyling, M. Behandlung follikulärer Lymphome. Info Onkol. 18, 30–40 (2015). https://doi.org/10.1007/s15004-015-0708-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-015-0708-x

Search

Navigation